Menu

China Vows to End Commercial Ivory Trade

Conservationists declare victory as the country agrees to crack down on domestic ivory sales, which have contributed to the near-extinction of elephant species.

Jan 4, 2017
Joshua A. Krisch

PIXABAY, SPONCHIAChina will enforce a new ban on commercial ivory, officials announced on December 30. The ban is set to go into effect by the end of 2017, The New York Times reported, and could cripple the efforts of elephant poachers in Africa, who sell most of their wares to China. “Certainly closing down domestic ivory in China will have a dramatic impact,” John Robinson of the Wildlife Conservation Society told NPR’s The Two-Way. “The Chinese market is the largest ivory market in the world.”

The World Wildlife Foundation estimates that 20,000 elephants are poached each year in Africa, most due to Chinese demand for ivory, the International Business Times reported. Skilled Chinese artisans typically carve the ivory into ornate patterns that can sell for thousands of dollars. China’s current stockpile of legal ivory is estimated to be worth roughly $150 million, The New York Times reported.

Although new ivory has been banned internationally since 1989, prior legislation has done little to slow the lucrative ivory market in China. Since the ban did not technically prohibit ivory taken before 1989, some unscrupulous dealers had exploited this loophole to pass off new ivory as old, pre-ban samples.

Whether China’s promise will reduce  illegal ivory trade remains to be seen, but in the meantime, conservationists are optimistic. “It’s a game changer,” Elly Pepper of the Natural Resources Defense Council told NPR. “[It] could be the pivotal turning point that brings elephants back from the brink of extinction.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.